Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia NHMRC (National Health and Medical Research Council) bolsters medical research with additional funds:

This article was originally published in Clinica

Executive Summary

Australia has granted new research funds of Aus$13.4m (US$10m) across 20 independent medical institutes, and a further Aus$8.5m will be provided towards the end of the year. The funds will be used to buy new equipment, upgrade infrastructure, improve technology, build on existing resources and employ more researchers and support staff. The funding is being managed by the National Health and Medical Research Council (NHMRC) and is part of the "Backing Australia's Ability Building Our Future through Science and Innovation" programme. Since 1999 Australia has significantly increased investment in health and medical research. It estimates that by the end of the year Aus$500m will have been spent.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel